# Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

> **NCT04127721** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Allogeneic Stem Cell Transplant Recipient
- Hematologic and Lymphocytic Disorder
- Hematopoietic and Lymphoid Cell Neoplasm

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **DRUG:** Itacitinib
- **DRUG:** Methotrexate
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT04127721
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09-22
- **Primary completion:** 2020-09-22
- **Final completion:** 2020-09-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 ACTUAL Enrollment must have Overall Recruitment Status
- **Last updated:** 2020-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04127721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04127721, "Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04127721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*